# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Acute myeloid leukemia

Acute Non Lymphoblastic Leukemia
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 61-70 of 671 results.
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Status: Recruiting
Last Changed: Jun 19, 2019
First Received: Jun 21, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy
Locations: Children's Hospital of Orange County, Orange, California, United States
Lucille Packard Children's Hospital Stanford University, Palo Alto, California, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Oct 25, 2019
First Received: May 12, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): Pracinostat, Placebos, Azacitidine
Locations: Mayo clinic hospital, Phoenix, Arizona, United States
Arizona Oncology Associates, East Valley Cancer Center, Tempe, Arizona, United States
University of Arizona cancer center-north campus, Tucson, Arizona, United States
10666 N.Torrey Pines-Scripps Cancer Center, La Jolla, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
... and 128 other locations.
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Status: Recruiting
Last Changed: Mar 02, 2020
First Received: Feb 21, 2019
Disease(s): Acute Myeloid Leukemia
Intervention(s): Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Locations: UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
University of Iowa Hospitals and Clinics; Investigational Drug Services, Iowa City, Iowa, United States
University of Kansas Clinical Research Center; Clinical Trials Office, Fairway, Kansas, United States
... and 28 other locations.
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
Status: Not yet recruiting
Last Changed: Jan 03, 2020
First Received: Jan 02, 2020
Disease(s): Acute Myeloid Leukemia
Intervention(s): Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
Status: Recruiting
Last Changed: Mar 10, 2020
First Received: Dec 31, 2018
Disease(s): Acute Myeloid Leukemia
Intervention(s): OmnImmune®
Locations: UHKT (Ustav hematologie a krevni transfuze), Praha, Czechia
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Status: Recruiting
Last Changed: Mar 27, 2020
First Received: Jun 09, 2017
Disease(s): Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Intervention(s): gilteritinib, LoDAC (Low Dose Cytarabine), MEC (Mitoxantrone, Etoposide, Cytarabine), FLAG (Granulocyte colony-stimulating factor (G-CSF), Fludarabine, Cytarabine)
Locations: Site CN103, Beijing, China
Site CN108, Beijing, China
Site CN109, Beijing, China
Site CN110, Beijing, China
Site CN112, Beijing, China
... and 46 other locations.
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Status: Recruiting
Last Changed: Mar 27, 2020
First Received: Nov 05, 2018
Disease(s): Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Intervention(s): gilteritinib, atezolizumab
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
University of Chicago, Chicago, Illinois, United States
Northwestern University, Chicago, Illinois, United States
University of Kentucky, Lexington, Kentucky, United States
Roswell Park Cancer Institute (RPCI), Buffalo, New York, United States
... and 9 other locations.
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Nov 20, 2019
First Received: Mar 30, 2018
Disease(s): Cancer - Acute Myeloid Leukemia
Intervention(s): Venetoclax, Dinaciclib
Locations: University of Arkansas /ID# 200016, Little Rock, Arkansas, United States
David Geffen School of Medicin /ID# 200015, Los Angeles, California, United States
The University of Chicago /ID# 200017, Chicago, Illinois, United States
Univ Maryland School Medicine /ID# 204015, Baltimore, Maryland, United States
Wake Forest Baptist Medical Center /ID# 200288, Winston-Salem, North Carolina, United States
... and 9 other locations.
Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients
Status: Recruiting
Last Changed: Nov 29, 2019
First Received: Jul 27, 2016
Disease(s): Acute Myeloid Leukemia
Intervention(s): pembrolizumab, Azacitadine
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland, United States
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Sep 25, 2019
First Received: Oct 23, 2017
Disease(s): Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Intervention(s): Cyclophosphamide
Locations: University of Colorado Denver, Aurora, Colorado, United States